Print

Lay Description

Evaluate effectiveness and safety in BRIUMVI® (ublituximab-xiiy) treated patients in real-world clinical practice. Observe patient demographics, baseline disease activity, and rationale for selecting BRIUMVI® (ublituximab-xiiy). 

Category

  • Nervous System
IRB Number
STUDY00000612
NCT Number
NCT # not yet entered

Eligibility

Eligible Ages
18+
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

  • ≥18 yr old patients with relapsing forms of MS 
  • Confirmed MS diagnosis
  • Patients who have not recieved BRIUMVI® infusion prior to enrollment
  • Patients prescribed BRIUMVI®, but have not yet recieved their first infusion on Day 1 of 150mg.

Exclusion Criteria

  • patients who have recieved any live or live-attenuated vaccines (including varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® administration
  • Any non-live vaccines within 2 weeks prior to first BRIUMVI® administration
  • Any active infection (e.g., Hepatitis B Virus [HBV]) 
  • Concurrent interventional MS trials or planned concurrent treatment with others MS DMT during study period.

Study Design

Arm Groups

Study Contact

Jannel Gamboa
gamboaj1@uthscsa.edu

Sarah Martinez
210-450-0569
martinezs23@uthscsa.edu

Charlotte Rhodes
210-450-8454
rhodesc1@uthscsa.edu

Luis Garcia
210-450-8451
garcial38@uthscsa.edu

Luis Garcia
210-450-8451
garcial38@uthscsa.edu

Principal Investigator
Tania Reyna